Patients with sickle cell disease urge FDA to greenlight landmark gene-editing treatment
The treatment is administered with a single infusion and was created by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, which has most of its employees in Mass.
Source: bostonglobe.com